www.skpcrossborder.com Nov 1, 2004
Your eye to India-centric and International updates
In the News

Transfer of Shares gets easier as FIPB gets liberal!!

A recent notification from the Reserve Bank of India (RBI) has allowed Indians to sell their stakes in Indian companies to foreign companies, without prior approval from the FIPB or the RBI. The reverse i.e. sale of foreign holding in Indian companies to Indians, is also allowed by the banking regulator.

However, the RBI notification states that the revised rules do not include financial services companies, including banks, non-banking finance companies and insurance companies. Transfers under the new norms should also adhere to the take-over rules of the Securities and Exchange Board of India (SEBI) and must be within the sectoral caps under the foreign direct investment 9FDI) rules.

The notification also specified that these sectors should be under the automatic route for FDI. Additionally, in case of transfer of shares of listed companies, the price of transfer should be in accordance with the pricing guidelines prescribed by SEBI and the RBI.

Cases involving increase in foreign equity participation by fresh issue of shares, as well as conversion of preference shares into equity capital, have been brought under the new rules. However such increase should also come under the respective sectoral caps and be allowed the automatic route.

Industry sources opine that the revised guidelines will reduce the time taken to complete take-overs involving foreign investors by 6-8 weeks, which is usually the time taken to get FIPB approval. Moreover, this will also save the investors and companies involved in the process the jurisdictions they had to give to the FIPB for taking over an Indian company. There is also a shift in the responsibility with the guidelines on chartered accountants involved in the deal, the companies and the people involved in the process and authorised foreign exchange dealers.

Print this ArticleTop

End of product patents makes India best bet for pharma MNCs

India's local drug companies have long benefited from a relaxed patent regime. All that is set to change from January 1 2005, when the country becomes fully TRIPs (Trade-Related aspects of Intellectual Property Rights)-compliant. Under the provisions of one of these arrangements, India must have a regime that grants pharmaceutical product patents by 2005. Failure to meet TRIPs requirements would jeopardize India's market access rights and other benefits under the WTO. This has signaled a significant change to drug companies, encouraging them to switch their efforts from producing generic drugs to getting actively engaged in R&D of their own molecules/pharmaceutical products and processes.

To support developments of this kind, the Indian government is providing a range of tax concessions designed to encourage R&D, including a 10-year tax holiday on income arising from R&D. India expects more patent filing in light of the new product patent regime. India's drug companies have already seen higher profits in product patents and so Indian companies and Indian inventors will come out as serious contenders for new product patents.

An increase in the number of patent filings by MNCs is one of the most expected developments in India, which highlights the recognition of talent and resources available in the country. Further, India has more pharmaceutical products approved by the US Food and Drug Administration (FDA) than any foreign country. As India tightens its patent laws, its drug companies are looking for ways to keep both researchers and manufacturing plants busy. The industry realized that the new product patent regime will cement India's position as a global pharmaceutical outsourcing hub and off-shore location for R&D, the manufacture and export of domestically produced generics and other support services including strategic services in patenting and related matters. India is becoming a desirable location for the outsourcing of patent drafting as well.

Another advantage that India has is that the Indian drug companies have good infrastructure facilities. Local companies can manufacture drugs at very low cost, while still using skilled manpower for research. Capital costs are also low. Further, many Indian players have good manufacturing practices approved by the FDA. Hence, the Indian pharmaceutical companies will definitely flourish in the national and international markets after the introduction of the product patent regime.

These above implications of the product patent regime will improve the Indian pharmaceutical and biotech industry, bringing the quality to high, globally recognized standard.

Our Say

Investment plans in the pharma sector are reportedly being ramped up 5-7 times for clinical trials in India. Further, some new innovations may soon hit domestic pharmacy shelves and domestic arms of MNC pharma companies are said to be arming themselves with legal help for any possible IPR disputes with domestic companies.

The change to product patent regime is said to be symbolic of India’s serious intention of honouring IPR and possibly a foolproof incentive to tempt MNCs to invest in clinical research and drug discovery from India, making it a global hub for clinical trials. The likes of Pfizer, Aventis, Novo Nordisk, Novartis, GlaxoSmithKline, Eli Lilly and Organon are planning to leverage much of their drug development activity through their Indian arms.

Print this ArticleTop
In the News
Transfer of Shares gets easier as FIPB gets liberal!!
End of product patents makes India best bet for pharma MNCs

Interesting Reads
Stop Press…well actually Press Note 18!!
Cenvat rule extends input tax credit across goods & services
“Metro”mania amongst BPO players dulls as newer entrants emerge
India’s outsourcing capabilities move up the value chain

Quick Links
Textile EOUs get duty relief on fabrics
Indian Sugar Market: too sweet to resist
BPOs decide location on City personality

India Inc
- Investment briefs
Ericsson to set up radio base stations in India
Wal-Mart to set up wholly-owned arm in India
Genesis acquires Smart Yantra
Teledata buys Bitech's Dubai arm
US' Qualcomm to work with local chip design firm
Suzuki to capitalize on India’s auto boom
Macquarie Bank plans Indian arm

Hope you enjoyed this edition of ‘eye to I’
Please feel free to mail us -
-
any suggestions / comments that would help us enhance this e-supplement
-
requests for further information or advice
-
a request to meet
© 2004 SKP Crossborder Consulting Pvt Ltd Email to a Friend | Unsubscribe | Feedback | Disclaimer